| Cat.No. | Name | Information |
|---|---|---|
| M2206 | TH-302 (Evofosfamide) | TH-302 is a highly potent and selective hypoxia-activated procompound targeting hypoxic regions of solid tumors with IC50 of 19 nM. |
| M6098 | Baicalein | Baicalein is a CYP2C9 and prolyl endopeptidase inhibitor, IC50 value of 3.12 mM. |
| M9325 | EGTA | EGTA is a specific calcium chelator with a Kd of 60.5 nM at physiological pH (7.4) and a high specificity for Ca2+ than for Mg2+.EGTA significantly inhibits the substrate adhesion capacity of inflammatory macrophages. |
| M9330 | Brij-35 | Brij-35 (Polidocanol) is a high HLB, ethoxylated, nonionic ether of lauryl alcohol with broad pH stability. |
| M6154 | 2-PMPA tetrasodium | 2-PMPA (PMPA tetrasodium salt) is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 300 pM. |
| M2250 | Pamidronate disodium | Pamidronate disodium is a nitrogen containing bisphosphonate, used to the research of preventing osteoporosis. |
| M9916 | DPPH | DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a stable free radical that measures the free radical scavenging activity of antioxidants. |
| M9194 | Insulin (human) | Insulin (human) is a polypeptide hormone that regulates the level of sugar (glucose) in the blood and is produced by beta cells of islets. |
| M3409 | Formestane | Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM. |
| M9665 | N-(2-amino-2-oxoethyl)acrylamide | N-(2-Amino-2-oxoethyl)acrylamide |
| M21579 | TDI-11861 | sAC inhibitors such as DI-11861 can be used effectively as a compound for on-demand, non-hormonal male contraception. |
| M21578 | ENT-01 | ENT-01 is an antibiotic. |
| M21577 | Sirpiglenastat | Sirpiglenastat (DRP-104) is a broad acting glutamine (glutamine) antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing an effective antitumor immune response. |
| M21576 | PTC258 | PTC258 is an oral, brain-penetrating splicing modulator targeting ELP1. |
| M21559 | ART615 | ART615 is a related isomer of ART558. ART615 is an inactive form of ART558, causing <10% Polθ inhibition at 12 μM, so it can be used as a control for ART558 (IC50=7.9 nM). |
| M21536 | BAY-069 | BAY-069 is a branched-chain amino acid transaminase (BCAT) 1/2 inhibitor. Involved in the synthesis and catabolism of branched-chain amino acids. |
| M21535 | UCB7362 | UCB7362 is an oral plasma protease X (PMX) inhibitor that is being developed as an anti-malarial compound. |
| M21534 | AN15368 | AN15368 is an oral cleavage and polyadenylate specific factor (CPSF3) inhibitor being developed for use in Chagas disease (also known as American trypanosomiasis). |
| M21532 | JNJ-64264681 | JNJ-64264681 is a covalent Bruton tyrosine kinase (BTK) inhibitor under development for hematological malignancies. |
| M21510 | Telaglenastat hydrochloride | Telaglenastat (CB-839) hydrochloride is a pioneering (first-in-class), selective, reversible, orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride has IC50 values of 23 nM and 28 nM for endogenous glutaminase in the kidney and brain of mice, respectively. Telaglenastat hydrochloride also induces autophagy and has strong antitumor activity. |
| M21493 | Omadacycline mesylate | Omadacycline (PTK 0796) mesylate, the first (first-in-class) orally active aminomethylcycline antibiotic, is a tetracycline antibiotic. Omadacycline mesylate can be used to study acute bacterial skin and skin structure infections, infectious pneumonia, and urinary tract infections. |
| M21485 | Acotiamide-d6 | Acotiamide-d6 (Z-338-d6 free base) is a deuterium substitute of Acotiamide. Acotiamide is a first-in-class gastrointestinal motility compound with oral activity that has the potential to be used in functional dyspepsia. |
| M21484 | MBC-11 trisodium | MBC-11 trisodium is a first-in-class coupling of bone-targeted ethyl bisphosphonate covalently bound to the antimetabolite cytarabine (Ara-C). MBC-11 trisodium has the potential to be used in neoplastic bone disease (TIBD). |
| M21483 | MBC-11 triethylamine | MBC-11 triethylamine is the first (first-in-class), bone-targeted ethyl bisphosphonate covalently bound conjugate to the antimetabolite cytarabine (araC). MBC-11 triethylamine has the potential to be used in neoplastic bone disease (TIBD).*The compound is unstable in solutions, freshly prepared is recommended |
| M21481 | MBC-11 | MBC-11 is a first-in-class, bone-targeted bisphosphonate conjugate covalently bound to the antimetabolite cytarabine (araC). MBC-11 has the potential to be used in neoplastic bone disease (TIBD). |
| M21480 | Varlilumab | Varlilumab (CDX-1127) is a first-in-class monoclonal antibody to human IgG1 against CD27. Varlilumab has antitumor activity. |
| M21474 | Nln activator 1 | Nln activator 1 is a first-in-class peptide neurolysin activator with enhanced brain permeability and stability. |
| M21455 | Casimersen | Casimersen (SRP-4045) is an antisense oligonucleotide of the subclass of phosphodiamide morphorph oligomers. Casimersen binds to exon 45 of dystrophin's precursor mRNA to restore the open reading frame (by skipping exon 45), resulting in an internally truncated but functional dystrophin. Casimersen can be used in the study of Duchenne muscular dystrophy (DMD). |
| M21423 | GB1211 | GB1211 is an oral galectin-3 inhibitor under development for the study of fibrotic diseases. |
| M21422 | ICeD-2 | ICeD-2 is a dipeptidyl peptidase 9 (DPP9) inhibitor that is being developed for HIV-1 infection. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
